Cannabix Technologies Develops Version 2.0 of THC Breath Analyzer
May 11 2020 - 8:45AM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company or Cannabix”) developer of marijuana breathalyzer devices
for law enforcement and the workplace, is pleased to report that
the Company has developed a new version of its THC Breath Analyzer
(“THCBA”) and is preparing for additional testing with the device.
Company engineers have updated several components in the THCBA and
have changed the form factor for improved handling. Cannabix
Technologies is on the forefront in research and development to
create point-of-care breath testing technologies for the detection
of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of
marijuana that causes impairment. The THCBA incorporates
microfluidic sensor technology for the detection of THC from
breath. New pictures of the THCBA version 2.0 advanced prototype
device are available on the Company’s website
(www.cannabixtechnologies.com) and included in this news release.
The THCBA has attractive features such as single-hand ergonomic
design and single-stage direct breath capability. Testing to
date, has shown from the time of sample intake, the device can
provide results in under 5 minutes. The THCBA uses a disposable
spit trap and provides easy to understand screen prompts for the
positive and negative detection of THC in breath. Studies¹
have shown that breath is a better indicator of impairment than
saliva, blood, or urine because THC is present in breath for a
relatively short period of time (1-3 hours); whereas, it is
excreted at detectable levels in other body fluids for many hours,
days, or even weeks after smoking. This short time period of
detection in breath aligns with the peak impairment window. The
Company has been developing the THCBA with Dr. Mina Hoorfar at
University of British Columbia (“UBC”) and has an exclusive
technology license agreement with UBC.
In the immediate term, Cannabix scientists will be testing the
THCBA 2.0 device with cannabis smokers in order to (a) have more
cannabis user data to enhance the device’s machine learning
database and (b) for continuous improvement purposes. It should be
noted that testing with cannabis smokers under general COVID-19
restrictions in place has become more time-consuming as device
sterilization and organizing multi-subject testing has become more
onerous. In the THCBA 2.0 version, several components have been
built using 3D printed technology for rapid prototyping and design
flexibility, and engineers have begun experimenting with different
materials and coatings that would be more advantageous in
manufacturing processes. Since early March, our
discussions with potential pilot/test-user groups were paused due
to the COVID-19 pandemic, however the Company is pleased to report
it is having renewed discussions with pilot-use cases and is
actively navigating how such studies will be done with enhanced
safety in mind.
Rav Mlait, CEO, stated, “Our team have been diligently pressing
forward with development of our marijuana breathalyzer devices
through the various constraints that the COVID-19 pandemic has
presented us and our suppliers. We have improved the design and
form factor of the THCBA and look forward to collecting more user
data.”
“We are pleased to be continuing our collaborative research
efforts with Cannabix towards the development of this technology
under these challenging circumstances,” stated Dr. Hoorfar.
The Company reports it is granting 1,790,000 incentive stock
options exercisable at $0.50 cents per share for five years to
officers, directors and two years for consultants.
(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath
and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis
Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid
Res.; 99-104.
Himes S. et al. 2013. Cannabinoids in Exhaled Breath following
Controlled Administration of Smoked Cannabis. Clinical Chemistry;
1780–1789.
Beck O, Sandqvist S, Dubbelboer I, Franck J. 2011. Detection of
delta9-tetrahydrocannabinol in exhaled breath collected from
cannabis users. J Anal Toxicol; 35:541– 4.
About Cannabix Technologies Inc.Cannabix Technologies Inc. is a
leader in marijuana breathalyzer development for law enforcement
and the workplace. Cannabix has established breath testing
technologies in the pursuit of bringing durable, portable tools to
market to enhance detection of marijuana impaired driving offences
on roads at a time when marijuana is becoming legal in many global
jurisdictions. Cannabix is working to develop drug-testing devices
that will detect THC- the psychoactive component of marijuana that
causes intoxication- using breath samples. In particular, Cannabix
is focused on developing breath testing devices for detection of
recent use of THC, in contrast to urine testing for THC metabolite
that requires an invasive collection and reflects usage, days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/a698bca7-6864-47ef-9a9a-a78a0901cdd4
https://www.globenewswire.com/NewsRoom/AttachmentNg/8d402dc0-d9cc-4e4b-910c-c04cdf7e7966
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Oct 2023 to Oct 2024